Ocugen, Inc. — Director's Dealing 2017

Oct 12, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2017-10-10

Reporting Person: Kennedy Stephen Richard (EVP and COO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-10	Employee Stock Option (Right to Buy)	$2.12	A	50000	Acquired	2027-10-09	Common Stock (50000)	Direct

Footnotes

F1: This option vests over four (4) years of continuous service following October 10, 2017, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and the balance vesting in thirty-six (36) equal monthly installments thereafter.